Chimerix to Present at Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Chimerix (NASDAQ:CMRX) will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 10:00 a.m. ET. Mike Sherman, the CEO, will lead the presentation. A live audio webcast will be accessible in the Investor Relations section of Chimerix's website, where it will remain archived for about 90 days. Chimerix is focused on developing treatments for cancer and serious diseases, with key programs including brincidofovir, ONC201, and dociparstat sodium, targeting conditions such as smallpox and acute myeloid leukemia.

DURHAM, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 10:00 a.m. ET.

A live audio webcast of the chat will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. The Company’s three most advanced clinical-stage development programs are brincidofovir (BCV), ONC201 and dociparstat sodium (DSTAT). BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a blinded independent central review is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.

CONTACT:

Investor Relations:
Michelle LaSpaluto
919 972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

FAQ

When will Chimerix present at the Jefferies Virtual Healthcare Conference?

Chimerix will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 10:00 a.m. ET.

Where can I watch the Chimerix presentation from the Jefferies Conference?

The presentation will be available via a live audio webcast on Chimerix's Investor Relations website, archived for approximately 90 days.

What are the main clinical programs of Chimerix?

Chimerix's main clinical programs include brincidofovir, ONC201, and dociparstat sodium, targeting smallpox and acute myeloid leukemia among other conditions.

Who is presenting for Chimerix at the Jefferies Conference?

Mike Sherman, the Chief Executive Officer of Chimerix, will be presenting at the conference.

What is the focus of Chimerix as a biopharmaceutical company?

Chimerix focuses on developing innovative medicines for cancer and other serious diseases.